[{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"b40fb89a-d042-4bf3-862c-f905fdac4d70","acronym":"VERSATILE-002","url":"https://clinicaltrials.gov/study/NCT04260126","created_at":"2021-01-18T20:42:10.407Z","updated_at":"2025-02-25T16:09:57.311Z","phase":"Phase 2","brief_title":"Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC","source_id_and_acronym":"NCT04260126 - VERSATILE-002","lead_sponsor":"PDS Biotechnology Corp.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Versamune HPV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-12-18"},{"id":"3ebe9afc-734e-40aa-b8ff-0cbea23c45dc","acronym":"IMMUNOCERV","url":"https://clinicaltrials.gov/study/NCT04580771","created_at":"2021-01-18T21:51:39.762Z","updated_at":"2024-07-02T16:34:59.039Z","phase":"Phase 2","brief_title":"A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial","source_id_and_acronym":"NCT04580771 - IMMUNOCERV","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Versamune HPV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 10/14/2020","start_date":" 10/14/2020","primary_txt":" Primary completion: 03/08/2025","primary_completion_date":" 03/08/2025","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2024-06-04"}]